---
title: 'Director, Clinical Pharmacology at Remix Therapeutics'
canonical: 'https://feeny.ai/job/director-clinical-pharmacology-remix-therapeutics-watertown-0wtvv2v3477g'
type: 'job'
last_seen: '2026-11-07'
---

# Director, Clinical Pharmacology at Remix Therapeutics

- **Company:** Remix Therapeutics
- **Location:** Watertown, MA
- **Posted:** 2026-10-26
- **Last confirmed live:** 2026-11-07
- **Apply:** https://job-boards.greenhouse.io/remixtherapeutics/jobs/4747667005

## Job description

Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's therapeutic approach led to the discovery of REM-422, an investigational small molecule designed to modulate RNA processing in oncology, currently being evaluated in two clinical programs, 1) the ARIA clinical study, a Phase 1/2 clinical study in adenoid cystic carcinoma (ACC), and 2) a Phase 1 clinical study in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS).

Position Summary:

The Director of Clinical Pharmacology will play a critical role in the design, execution, analysis, and interpretation of clinical pharmacology strategies across Remix Therapeutics' development programs. The initial focus of the role will be to lead the integrated clinical pharmacology strategy for REM-422, with primary responsibility for supporting late-stage development and potential regulatory submissions. The role will also provide clinical pharmacology leadership for emerging pipeline programs to support IND-enabling and early clinical development strategies.

The successful candidate will work in a highly cross-functional environment, partnering closely with Clinical Development, Regulatory Affairs, Clinical Operations, Biostatistics, DMPK, CMC and external collaborators to drive data-driven decision making and advance clinical development.

This is an opportunity to own the clinical pharmacology strategy for REM-422 as it advances toward a potential NDA, which would be Remix's first. You will shape dose selection, labeling, and regulatory strategy for an oral RNA-targeting therapy in ACC and AML/HR-MDS, and set the clinical pharmacology approach for the pipeline programs coming behind it.

Key Responsibilities:

- Lead the integrated clinical pharmacology strategy for REM-422, with primary responsibility for supporting late-stage development and potential regulatory submissions.
- Drive dose optimization for REM-422 consistent with FDA Project Optimus expectations, including population PK, exposure–response, and model-informed drug development analyses.
- Design and oversee clinical pharmacology studies evaluating food effect, drug–drug interactions, absorption and metabolism, and other intrinsic and extrinsic factors affecting REM-422 exposure.
- Represent Clinical Pharmacology in regulatory interactions and lead relevant components of briefing documents and regulatory submissions.
- Provide clinical pharmacology leadership for emerging pipeline programs, translating nonclinical pharmacology, ADME, PK, and toxicology data into integrated IND-enabling and early clinical development strategies.
- Support human PK projections, first-in-human dose selection, dose-escalation design, PK/PD assessments, and early identification of clinical pharmacology risks.
- Partner cross-functionally and oversee external vendors to ensure high-quality, timely delivery of studies, analyses, models, and regulatory documentation.

Qualifications:

- PhD, PharmD, or MD with relevant training in clinical pharmacology, pharmaceutical sciences, or a related discipline.
- 10+ years of clinical pharmacology experience in the biotech or pharmaceutical industry, including oncology and clinical-stage development.
- Demonstrated expertise in clinical pharmacology strategy and study design from early development through registration.
- Direct experience contributing to an NDA/MAA submission, including authoring clinical pharmacology sections of the filing.
- Deep understanding of PK/PD principles, modeling and simulation, and exposure–response analysis.
- Proven cross-functional leadership and ability to integrate complex scientific data into strategic development decisions.
- Excellent communication skills, with the ability to present to senior leadership and external stakeholders.

Salary Range:

$206,000 - $252,000 USD

This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable.  Actual salaries may vary based on factors, such as skill, experience, and qualification for the role.

## About Remix Therapeutics

## Company Overview
- **One-liner**: Clinical-stage biotechnology company developing first-in-class oral small molecule therapies that reprogram RNA processing to address previously undruggable drivers of cancer and other diseases.
- **Entity Type**: Private (Venture-backed; merged with Passage Bio in June 2026 with a concurrent $100M private placement)
- **Headquarters**: Watertown, Massachusetts, United States
- **Founded**: 2018
- **Founders**: Peter Smith, PhD

## Core Business
- **Primary industry**: Biotechnology – RNA-targeted therapeutics, oncology
- **Target customers**: B2B (pharmaceutical partners like Roche and Johnson & Johnson) and B2C (patients with high-unmet-need cancers, served through healthcare providers)
- **Mission or purpose statement**: “Reprogramming RNA to transform patients’ lives” – focused on modulating RNA processing to address disease drivers at their origin

## Products & Services
- **REM‑422**: First-in-class, orally available small molecule mRNA degrader targeting the historically undruggable transcription factor MYB. Currently in Phase 1 clinical trials for acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR‑MDS), and adenoid cystic carcinoma (ACC). Granted FDA Fast Track designation for ACC.
- **REMaster™ Drug Discovery Platform**: Proprietary platform that designs small molecules to harness cellular RNA‑processing machinery, enabling modulation of gene expression for targets previously considered intractable. Used for internal pipeline and partnered programs.

## Market Standing
- **Valuation/Market Cap**: Not publicly disclosed (private company; post-merger valuation unknown)
- **Key Metric**: Total funding ~$240.7M (including a $100M private placement concurrent with the Passage Bio merger in June 2026). Annual revenue (2025 estimate): $3.2M (typical for a clinical‑stage biotech).
- **Notable Investors/Partners**:  
  - Investors: Surveyor Capital (Series B lead, $70M), Foresite Capital (Series A lead, $65M), The Column Group (Venture Round lead, $60M)  
  - Partners: Roche (collaboration for RNA‑processing modulators), Johnson & Johnson Innovative Medicine (multi‑year, three‑target oncology/immunology collaboration)  
- **Growth Signals**:  
  - Preliminary Phase 1 data for REM‑422 showed strong anti‑tumor activity and favorable safety in ACC  
  - FDA Fast Track designation for REM‑422 in ACC  
  - Merger with Passage Bio (June 2026) brings additional capital and pipeline synergies  
  - Active job postings up 200% month‑over‑month and quarter‑over‑quarter  
  - Headcount of 49 employees with a heavy concentration in research (43%)

## Competitive Advantages
- **Proprietary REMaster platform** uniquely enables oral small‑molecule modulation of RNA processing, expanding the druggable target space beyond traditional protein inhibition
- **First‑in‑class oral MYB mRNA degrader** (REM‑422) addresses a transcription factor long considered undruggable
- **Top‑tier pharma collaborations** with Roche and J&J validate the technology and provide non‑dilutive funding
- **Strong scientific leadership** (CEO/co‑founder Peter Smith, PhD, formerly CSO at H3 Biomedicine, where he advanced three molecules to the clinic)

## Strategic Focus
- Advance REM‑422 through Phase 1 trials across multiple MYB‑driven cancers (AML, HR‑MDS, ACC) and expand into additional solid tumors
- Leverage the REMaster platform to discover new RNA‑processing modulators for oncology and immunology
- Deepen existing pharma partnerships and seek new collaborations to accelerate pipeline growth
- Integrate the recently merged Passage Bio assets and utilize the $100M private placement to fund clinical development

## Why Work Here
- **Culture**: Values-driven environment centered on “True to Our RNA” (scientific integrity), “Courageous Curiosity” (bold innovation), and “Remixing Together” (collaboration and mutual support). Employees describe a flat, science‑first culture where diverse perspectives are welcomed.
- **Work model**: Hybrid? While not explicitly stated, the company has three offices in the Boston area (Watertown HQ, One Kendall Square Cambridge, and another Cambridge location). Lab‑based roles are likely on‑site; corporate roles may offer flexibility.
- **Perks & environment**: Small company (~49 people) with the energy of a startup but backed by significant funding and pharma partnerships. Employees share a strong sense of mission to bring new therapies to patients with few options. “We take our work seriously but not ourselves.”
- **Growth opportunity**: Rapidly advancing clinical pipeline and post‑merger expansion offer career advancement in a high‑visibility biotech. Recent ramp‑up in hiring (3 active postings for senior leadership roles like VP of Program Team Lead, VP of Biostatistics, and Senior Manager of Strategy & BD) signals scaling.

## Sources
1. [Remix Therapeutics Home](https://www.remixtx.com/)
2. [Remix Therapeutics About Us](https://www.remixtx.com/about/)
3. [Remix Therapeutics Join Us](https://www.remixtx.com/join/)
4. [Remix Therapeutics LinkedIn](https://www.linkedin.com/company/remix-therapeutics)
5. [Remix Therapeutics Greenhouse Careers](https://job-boards.greenhouse.io/remixtherapeutics)

## Other roles at Remix Therapeutics

- [Director, Commercial Project Management & Launch Excellence](https://feeny.ai/job/director-commercial-project-management-launch-excellence-remix-therapeutics-r7bj18tryxga) — Watertown, MA
- [Senior Director, GCP Quality](https://feeny.ai/job/senior-director-gcp-quality-remix-therapeutics-watertown-ancn66bxrnf3) — Watertown, MA
- [Associate Director, Clinical Data Management](https://feeny.ai/job/associate-director-clinical-data-management-remix-therapeutics-watertown-qq070g410ywh) — Watertown, MA
- [Head of Medical Affairs](https://feeny.ai/job/head-of-medical-affairs-remix-therapeutics-watertown-x0b0ddpp9nnc) — Watertown, MA
- [Vice President/Senior Director, Nonclinical Drug Safety & Toxicology](https://feeny.ai/job/vice-president-senior-director-nonclinical-drug-safety-toxicology-remix-hcv58wta0q0b) — Watertown, MA
- [Vice President, Clinical Development](https://feeny.ai/job/vice-president-clinical-development-remix-therapeutics-watertown-0ewyfa0bvx9g) — Watertown, MA
- [Director, Clinical Pharmacology](https://feeny.ai/job/director-clinical-pharmacology-seaport-therapeutics-boston-emw9as8mns26) — Boston, MA
- [Director, Clinical Pharmacology](https://feeny.ai/job/director-clinical-pharmacology-mirum-pharmaceuticals-foster-city-hgkvgcbm9zz4) — Foster City, CA
- [Director, Clinical Pharmacology](https://feeny.ai/job/director-clinical-pharmacology-relationrx-london-wpw6zyh37q45) — London, United Kingdom